Vishal Saini, MD
Sleep Medicine · Saginaw, MINPI 1477866390
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $107,320 of the $175,510 with a category attached, or 61.1%. Jazz Pharmaceuticals Inc. accounts for 66.9% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $58,587, more than ten times the $265 reported in 2019. Among sleep medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 403 payments — averaging $435.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$117K
- Axsome Therapeutics, Inc.$42K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- Inspire Medical Systems, Inc.$3K
- ZOLL Respicardia, Inc.$1K
- Eisai Inc.$1K
- plus $2K from 14 others
Across 348 payments — averaging $1377.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$431K
- Jazz Pharmaceuticals Inc.$49K
What the payments were for
- Consulting fees$31,90118%
- Speaking & faculty fees$107,32061%
- Travel & lodging$25,65015%
- Food & beverage$10,4416%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 179 | $117,422 |
| Axsome Therapeutics, Inc. | 77 | $42,334 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $8,582 |
| Inspire Medical Systems, Inc. | 24 | $3,094 |
| ZOLL Respicardia, Inc. | 5 | $1,372 |
| Eisai Inc. | 15 | $1,142 |
| Harmony Biosciences LLC | 49 | $915 |
| Idorsia Pharmaceuticals US Inc | 14 | $219 |
| Resmed Corp | 5 | $90 |
| Pfizer | 6 | $85 |
| Merck | 3 | $42 |
| Amgen | 3 | $41 |
| Novo Nordisk | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $25 |
| AbbVie | 2 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XYWAV$110,589
- SUNOSI$41,108
- Inspire Upper Airway Stimulation System$1,361
- remede System$1,306
- Inspire$1,181
- XYREM$253
- Dayvigo$115
How this compares
$175,510 in reported general payments places this provider in the 95th percentile of 78 sleep medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 19 | $324,312 |
| SunosiSolriamfetol Hcl | 14 | $14,621 |
| BelsomraSuvorexant | 13 | $8,063 |
| Modafinil | 68 | $4,977 |
| Doxepin Hcl | 31 | $1,154 |
| Temazepam | 17 | $975 |
| Zaleplon | 22 | $746 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 29 | $404 |
| Ropinirole Hcl | 39 | $350 |
| Zolpidem Tartrate | 46 | $237 |
| Eszopiclone | 15 | $192 |
| Trazodone Hcl | 20 | $152 |
| Gabapentin | 20 | $141 |
| Quetiapine Fumarate | 11 | $139 |
| Zolpidem Tartrate ErZolpidem Tartrate | 12 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Axsome Therapeutics, Inc.Sunosi | $42,334 | $14,62114 claims |
| MerckBelsomra | $42 | $8,06313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 78 sleep medicine providers in Michigan.
Other sleep medicine in Saginaw
- Vishal PatelRoyal Oak$507K
- Oktai MamedovEast Lansing$62K
- Nathan BossCharlevoix$43K
- Kelly WatersGrand Rapids$30K
- Abdul MalikTraverse City$12K
- Albert HoGrand Rapids$10K
- Emad AlatassiRoseville$9K
- Zachary RichensPortage$6K
- Michel AlkhalilTroy$6K
- Alice DoeKalamazoo$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.